The standard Health Canada review timeline for generic drug applications is 180 days, though complex submissions may require additional time for assessment
However, based on the clinical trial criteria used in studies such as the Phase 2 trial published in the New England Journal of Medicine (2023), researchers have investigated its use in adults with: Obesity , defined as a body mass index (BMI) of 30 kg/m or above Overweight (BMI 27 kg/m or above) with at least one weight-related comorbidity, such as hypertension, dyslipidaemia, or obstructive sleep apnoea Type 2 diabetes , where improved glycaemic control alongside weight reduction is a treatment goal In clinical trials, participants were typically adults without a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2)
For high-performing individuals looking to fine-tune their health, this means better blood sugar control, more stable energy, and a reduced risk of developing metabolic issues down the line
PMID 12451146
Reconstitute a GLOW-70 vial by adding 2.5 mL of BAC water That delivers a concentration of 28 mg/mL The resulting dose per injection: 2.8 mg 28 mg/mL = 0.1 mL or 10-units on a U-100 insulin syringe Each 70 mg vial of GLOW supplies 25 daily doses and remains within the 28-day refrigerated-use window